CureVac Jumps on EU Vaccine Talks Days After Sky-High IPO By Investing.com

© Shutterstock

By Christiana Sciaudone

Investing.com —   CureVac jumped 14% after the EU concluded a first round of talks for 225 million doses of a potential Covid-19 vaccine.

Curevac Bv (NASDAQ:) went public on Aug. 14, when it soared almost 250%. The company, backed by the Bill & Melinda Gates Foundation, is focused on using messenger RNA to treat diseases. The IPO raised more than $213 million.

The EU is also in talks with Johnson & Johnson (NYSE:) and Sanofi (NASDAQ:) for their vaccines under development, and agreed last week an advanced purchase deal with AstraZeneca (NYSE:) for at least 300 million doses of the shot it is developing with Oxford University, Reuters reported. CureVac said the talks included an option to supply 180 million additional doses.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*